Tilray and Canopy Stocks Rise Following Reports of Trump's Plans to Ease Marijuana Regulations
Cannabis Stocks Surge: Tilray Brands and Canopy Growth experienced a significant increase in stock prices.
Federal Policy Change: The surge was attributed to reports that President Donald Trump plans to ease federal restrictions on marijuana.
Trade with 70% Backtested Accuracy
Analyst Views on WEED
About the author

Advisors Share Insights: Advisors are providing insights on the cannabis market, focusing on investment opportunities and trends.
Pursue US Cannabis ETF: There is a growing interest in establishing a US-based cannabis exchange-traded fund (ETF) to capitalize on the expanding market.
Market Growth Potential: The cannabis industry is projected to grow significantly, with estimates suggesting a potential 20% increase in market value.
Investment Strategies: Advisors are discussing various investment strategies to navigate the complexities of the cannabis sector effectively.

Market Response: U.S. listed shares of cannabis companies have seen an increase following reports that the U.S. Senate is considering reclassifying marijuana.
Legislative Developments: The potential reclassification of marijuana could lead to significant changes in the cannabis industry, impacting regulations and market dynamics.

Canopy Growth Performance: Canopy Growth reported an increase of 18.7% in its performance metrics.
Tilray Brands Growth: Tilray Brands experienced a growth of 13% in its operations.
Cronos Group Increase: Cronos Group saw a 9% rise in its performance.
SNDL Growth Rate: SNDL reported an increase of 11.6% in its metrics.
- Market Reaction: Traders are currently driving down the prices of pot stocks.
- Executive Order Impact: The negative sentiment may overlook the potential positive effects of President Trump's executive order aimed at reducing restrictions on cannabis products.
- Cannabis Stock Reaction: Cannabis stocks experienced a decline on Thursday.
- Executive Order Impact: The drop followed President Donald Trump's signing of an executive order to reschedule marijuana as a lower-class drug.







